Ann: Imugene Advances to Phase 2 in Gastric Cancer Trial, page-190

I was at a presentation some time back and Leslie Chong said she had lead a number of purchasing deals when she was at Genentech, her last deal being around $US800m ($AUD1.1Billion).

Leslie and Axel Hoos have an enormous amount of experience on how to maximize the $ amount Pharma will pay.

I believe they are carefully creating a company with a platform that if the science proves up has the potential too disrupt the T Cell market, it’s not just about Her-Vaxx.

These next results are another value enhancing piece in the building block. It’s not short term as the future $ upside could be bloody Big

The executive team are now appropriately aligned with shareholders and the upside for all could be rather disruptive